Last updated: June 19, 2026

Avibactam sodium plus ceftazidime is a branded hospital-focused antibiotic franchise in the cephalosporin/β-lactamase inhibitor class. The financial trajectory is shaped by (1) steeper resistance-driven pull for approved indications, (2) competitive substitution against other cephalosporin- and carbapenem-based β-lactamase inhibitor regimens, and (3) post-approval price and formulary pressure typical of high-cost inpatient antibiotics. The product’s earnings profile depends on country-level reimbursement, stewardship formularies, hospital contracting cycles, and loss of exclusivity timing for branded combinations.

What are the market dynamics for avibactam sodium/ceftazidime (hospital antibiotic demand, resistance trends, and formulary pull)?

Quick answer: Demand tracks multidrug-resistant Gram-negative burden and guideline inclusion for specific β-lactamase phenotypes; growth is offset by contracting pressure and substitution to competing β-lactamase inhibitor combinations and carbapenem strategies.

How resistance patterns drive utilization

Avibactam (a β-lactamase inhibitor) paired with ceftazidime targets β-lactamase mechanisms that otherwise blunt ceftazidime activity. Market utilization rises when surveillance and hospital antibiograms show increased prevalence of susceptible organisms for the approved spectrum (commonly Enterobacterales and certain non-fermenters where resistance is mediated by inhibitor-sensitive enzymes). In practice, stewardship teams generally tie usage to:

confirmed or strongly suspected β-lactamase-mediated resistance patterns
adherence to local susceptibility reporting
attempts to preserve broader-spectrum agents

What hospital buying behavior does to sales growth

The combination is predominantly sold into inpatient settings with:

annual and multi-year GPO and IDN contracts
tender-based procurement
formulary placement tied to local antimicrobial stewardship committees

This creates a “slow commercial ramp, fast price pressure” pattern when new competitors enter or when branded-to-generic dynamics begin.

Competitive substitution levers

Substitution risk is structurally higher for broad hospital antibiotic classes than for niche outpatient drugs because hospitals can switch regimens by:

updating empiric protocols
selecting on susceptibility outcomes and total cost
using alternative inhibitors with overlapping spectrum

Key substitution vectors include:

other ceftazidime/β-lactamase inhibitor combinations
carbapenem-based regimens with inhibitors
newer or locally preferred empiric pathways

Which drugs compete with avibactam sodium/ceftazidime, and how do the competitive dynamics affect revenue?

Quick answer: The competitive set is concentrated in β-lactam/β-lactamase inhibitor and carbapenem-inhibitor hospital antibiotics. Revenue outcomes depend on guideline adoption, susceptibility performance in target pathogens, and negotiated hospital pricing.

Direct category competitors (practical substitution)

Within the Gram-negative hospital antibiotic category, clinicians and hospitals benchmark combinations on spectrum, inhibitor coverage breadth, dosing practicality, and outcomes in resistant phenotypes. Competitive pressure generally increases when:

a rival regimen offers better coverage against additional resistance mechanisms
outcomes data support reduced time-to-appropriate therapy
payers push toward lower net price via formulary tiering

Non-direct competition via stewardship protocol changes

Even when spectrum is not identical, stewardship protocols can shift because hospitals:

prefer agents with simpler dosing or administration workflows
standardize on one or two regimens to reduce inventory complexity
apply de-escalation rules that reduce the use of certain “reserve” combinations

These dynamics can compress sales even if the drug remains clinically valuable.

How does Orange Book and regulatory status shape the financial trajectory of avibactam sodium/ceftazidime?

Quick answer: The financial trajectory is driven by whether the branded combination retains protected dosage forms, methods, and clinical-use claims, and whether FDA recognizes eligible generic entry pathways.

What matters for FDA exclusivity and generic entry risk

For combination injectables, risk typically comes from:

Orange Book-listed patents expiring and/or becoming challengeable
Paragraph IV filings for generic versions
authorized generics or importation structures in some markets
labeling or manufacturing-specific restrictions that delay true launch

What matters for hospital formulary stability

Even with patent risk, hospitals may continue using a brand if:

generic supply is unreliable in certain geographies
quality processes are slower to scale
formulary contracts lock in branded procurement

What patent estate typically protects avibactam sodium/ceftazidime (composition, formulation, and method-of-use), and when does exclusivity end?

Quick answer: The patent estate for antibiotic combinations usually spans core active-ingredient composition, specific inhibitor/cephalosporin ratios, and formulation or manufacturing method claims. The revenue clock depends on expiration of each listed patent and any pediatric or data exclusivity triggers.

How patent expiration translates into financial impact

When core composition patents expire, generic entry risk rises, but actual sales losses depend on:

whether remaining formulation or method patents are still enforceable
litigation outcomes and settlement terms
whether generic companies can file under “non-infringing” design-arounds
hospital net price changes following competitors’ launch

When do potential generics or biosimilars create launch risk for the combination?

Quick answer: Generic launch risk is primarily about chemically synthesized injectable combinations. Biosimilar risk does not apply to small-molecule cephalosporin/β-lactamase inhibitor combinations.

What generic entry scenarios look like

A realistic financial pathway generally follows one of three patterns:

Litigation delayed launch: branded maintains higher revenues until a court or settlement allows entry.
Early settlement with shared market economics: branded loses price premium but retains partial volume via contract or limited entry dates.
Uncontested or fast-entry generic launch: accelerated discounting starts immediately after the earliest permission date, compressing brand net sales.

What financial trajectory has avibactam sodium/ceftazidime followed (growth, pricing pressure, and margin impact)?

Quick answer: The trajectory for hospital antibiotics typically shows early adoption and utilization gains followed by margin compression from contracting and competition, with acceleration or deceleration tied to resistance trends and new product introductions in the category.

Components of revenue performance

Revenue usually breaks into:

volume (courses of therapy administered)
net price (discounts, rebates, contract tiering)
mix (facility type, geography, and severity-based dosing patterns)

Margin impact mechanics

Gross margin erosion often comes from:

higher ASP volatility due to contract renegotiation
increased trade spend to retain IDNs
cost of supply and sterility assurance for injectables

Net margin then depends on SG&A intensity and manufacturing throughput scaling.

How does pricing and contracting in hospitals affect net sales trajectory for the antibiotic combination?

Quick answer: Net price is the main near-term driver after initial adoption because antibiotic contracting is discount-heavy and highly sensitive to competitor entry and tender outcomes.

Typical contracting features that pressure brand pricing

Hospitals and IDNs often:

issue tenders and award by lowest net cost
require rebates tied to volume commitments
switch agents on short renewal cycles once multiple suppliers are viable

How substitution can be managed commercially

Brands can reduce sales loss through:

stewardship-aligned evidence generation
expanded guideline inclusion
procurement leverage via bundled contracting and inventory assurance programs

What does the competitive landscape look like in major markets (US, EU5, UK, Japan) for avibactam sodium/ceftazidime?

Quick answer: The competitive intensity is highest where:

multiple β-lactamase inhibitor regimens are listed on formularies
tender processes favor lowest cost
patent cliffs or generic launch permissions are approaching

Market-specific dynamics that matter to financial outcomes

US: Faster contracting shifts and greater exposure to Paragraph IV-driven pricing moves.
EU5 and UK: Reimbursement and hospital procurement structures shape uptake; price controls can compress net revenues sooner.
Japan: Different tender and pricing approval cycles affect timing of price compression and substitution.

What patent litigation affects avibactam sodium/ceftazidime (infringement, settlement, and generic launch timing)?

Quick answer: Patent litigation and settlements determine when generic competitors can launch and at what market share, directly impacting the brand’s post-exclusivity net sales decline slope.

How to read litigation outcomes for financial planning

Key plan-impact elements include:

earliest permissible launch date in a settlement
whether launch is “at risk” for generics before full resolution
scope of injunctions tied to specific dosage forms or labeling

Because antibiotic injectables often have multiple patent families, partial settlements can still preserve brand pricing in some segments.

How does avibactam sodium/ceftazidime compare with competing β-lactamase inhibitor regimens on value and adoption?

Quick answer: Adoption depends less on headline spectrum than on stewardship fit, local susceptibility patterns, dosing practicalities, and negotiated net cost relative to alternatives.

Where clinical differentiation most often changes procurement

Procurement shifts when:

outcomes in key resistant phenotypes match or exceed alternatives
stewardship committees adopt a narrow “first-line” positioning
safety or administration advantages reduce operational burden

What product lifecycle risks exist for continued financial performance?

Quick answer: The principal risks are (1) formulation or method patent losses that open generic entry, (2) competitor pipeline launches that re-rank formulary placement, and (3) rising contracting pressure that converts clinical strength into lower net prices.

Lifecycle risk checklist for business planning

Patent cliff proximity and enforceability of remaining families
Likelihood of Paragraph IV challenges and settlement terms
Tender schedule sensitivity in key accounts
Expected competitor net price trajectories after entry
Labeling restrictions or data updates that preserve stewardship positioning

Key data table: financial drivers and likely inflection points

Driver	What moves it	Likely impact on net sales	Typical inflection timing
Volume utilization	Resistance prevalence and guideline inclusion	Increases courses of therapy	6-24 months after protocol adoption
Net price	Tender wins, rebate pressure, competitor entry	Compresses ASP/price premium	3-12 months around competitor launches
Mix shift	Facility type, severity, geography	Improves or harms revenue quality	Ongoing, accelerates in outbreaks
Patent enforceability	Composition/formulation/method families	Delays or accelerates generic discounts	Near expiration windows
Litigation/settlements	Launch permissions and scope	Determines launch date and discount speed	Typically 1-3 years around challenges
Supply readiness	Contract manufacturing and sterile fill-finish	Impacts fill rates and revenue capture	Any time near major contract changes

Key Takeaways

Avibactam sodium plus ceftazidime sales dynamics are driven by inpatient antibiotic utilization, resistance-pattern stewardship, and high-sensitivity hospital contracting.
Competitive substitution in Gram-negative hospital antibiotics compresses net price faster than it compresses volume, shaping margin trajectory.
Generic entry risk is primarily patent-and-litigation driven for this small-molecule injectable combination; biosimilar risk is not applicable.
Financial inflection points track patent expiration windows and settlement terms that govern earliest permitted launch and at-risk competition.

FAQs

How do hospital antimicrobial stewardship guidelines determine when avibactam/ceftazidime is used for multidrug-resistant Gram-negative infections?
What factors most influence net price and rebate intensity for hospital injectable antibiotics like avibactam sodium/ceftazidime?
Which patent families (composition, formulation, methods) typically delay generic entry for antibiotic combinations?
How do Paragraph IV challenges and settlements change the slope of brand revenue decline after exclusivity?
What competitive indicators (tender outcomes, formulary placement, alternative regimen adoption) predict future sales compression?

References

FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
U.S. Patent and Trademark Office (USPTO). Patent assignment and bibliographic records (where applicable).
Clinical practice guideline publications for hospital-acquired and ventilator-associated bacterial pneumonia and complicated urinary tract infection (various years and organizations).

International Patents:	195
US Patents:	7
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for avibactam sodium; ceftazidime
DailyMed Link:	avibactam sodium; ceftazidime at DailyMed

Sponsor	Phase
Qilu Pharmaceutical Co., Ltd.	PHASE3
Ain Shams University	PHASE2

Drug Class	Cephalosporin Antibacterial beta Lactamase Inhibitor
Mechanism of Action	beta Lactamase Inhibitors

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial		Y		⤷ Start Trial
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y			⤷ Start Trial
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y	Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015	⤷ Start Trial	⤷ Start Trial
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015	⤷ Start Trial	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Country	Patent Number	Title	Estimated Expiration
African Regional IP Organization (ARIPO)	1614	New heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents.	⤷ Start Trial
Argentina	031716	DERIVADOS DE 1-AZA Y 1,3- DIAZABICICLOETANOS Y ANALOGOS, UN PROCEDIMIENTO PARA SU PREPARACION, Y COMPOSICION FARMACEUTICA Y MEDICAMENTOS COMO ANTIBACTERIANOS	⤷ Start Trial
Austria	263768		⤷ Start Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1307457	C 2016 055	Romania	⤷ Start Trial	PRODUCT NAME: AVIBACTAM SAU O SARE A ACESTUIA; NATIONAL AUTHORISATION NUMBER: EU/1/16/1109; DATE OF NATIONAL AUTHORISATION: 20160624; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/16/1109; DATE OF FIRST AUTHORISATION IN EEA: 20160624
1480644	58/2016	Austria	⤷ Start Trial	PRODUCT NAME: KOMBINATION AUS CEFTAZIDIM UND AVIBACTAM; REGISTRATION NO/DATE: EU/1/16/1109 (MITTEILUNG) 20160628
1480644	PA2016037,C1480644	Lithuania	⤷ Start Trial	PRODUCT NAME: FARMACINIS MISINYS ARBA DERINYS, APIMANTIS KAIP VEIKLIUOSIUS INGREDIENTUS (1) CEFTAZIDIMA ARBA JO DRUSKA IR (2) AVIBAKTAMA ARBA JO DRUSKA; REGISTRATION NO/DATE: EU/1/16/1109/001 20160624
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Summary for avibactam sodium; ceftazidime

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for avibactam sodium; ceftazidime

Recent Clinical Trials for avibactam sodium; ceftazidime

Pharmacology for avibactam sodium; ceftazidime

Anatomical Therapeutic Chemical (ATC) Classes for avibactam sodium; ceftazidime

Paragraph IV (Patent) Challenges for AVIBACTAM SODIUM; CEFTAZIDIME